苏州颐华生物医药技术有限公司

Suzhou Yihua Biological Medicine Technology is a clinical-stage Chinese biopharmaceutical company specializing in the development of innovative therapeutics derived from natural products and marine resources. The company's lead candidate, Anyu Peibo Capsule (安郁沛勃胶囊), is a natural product-derived small molecule (amide alkaloids from Piper laetispicum) currently in Phase 3 clinical trials in China for the treatment of depressive disorder. Additionally, Suzhou Yihua is developing YH-Z-02, a marine-derived small molecule polysaccharide (depolymerized holothurian glycosaminoglycan) targeting pancreatic cancer, which received IND clearance from the US FDA in late 2025. Through its unique focus on natural and marine-derived drug discovery, the company aims to address significant unmet needs in mental health and oncology.